Congenital Cytomegalovirus Testing Outcomes From the ValEAR Trial

• Published in: Otolaryngology-head and neck surgery 2024-05, Vol.170 (5), p.1430-1441
• Main Authors: Orb, Quinn T., Pesch, Megan, Allen, Chelsea M., Wilkes, Ashlea, Ahmad, Iram, Alfonso, Kristan, Antonio, Stephanie Moody, Mithal, Leena Bhattacharya, Brinkmeier, Jennifer V., Carvalho, Daniela, Chan, Dylan, Cheng, Alan G., Chi, David, Cohen, Michael, Discolo, Christopher Michael, Duran, Carlos, Germiller, John, Gibson, Laura, Grunstein, Eli, Harrison, Gail, Lee, Kenneth, Hawley, Karen, Kohlhoff, Stephan, Melvin, Ann, MacArthur, Carol, Nassar, Michel, Neff, Laura, Pecha, Phayvanh, Salvatore, Christine, Schoem, Scott, Virgin, Frank, Saunders, James, Schleiss, Mark, Smith, Richard J. H., Sood, Sunil, Park, Albert H.
• Format: Article
• Language: English
• Subjects: congenital cytomegalovirus; COVID-19 - diagnosis; COVID-19 - epidemiology; Cytomegalovirus Infections - congenital; Cytomegalovirus Infections - diagnosis; Cytomegalovirus Infections - epidemiology; Dried Blood Spot Testing; Female; hearing‐targeted cytomegalovirus testing; Humans; Infant, Newborn; Male; Neonatal Screening - methods; pediatric hearing loss; Prospective Studies; United States - epidemiology; universal cytomegalovirus testing
• ISSN: 0194-5998; 1097-6817
• DOI: 10.1002/ohn.670

Objective To determine the positivity rate of congenital cytomegalovirus (cCMV) testing among universal, hearing‐targeted CMV testing (HT‐cCMV) and delayed targeted dried blood spot (DBS) testing newborn screening programs, and to examine the characteristics of successful HT‐cCMV testing programs. Study Design Prospective survey of birth hospitals performing early CMV testing. Setting Multiple institutions. Methods Birth hospitals participating in the National Institutes of Health ValEAR clinical trial were surveyed to determine the rates of cCMV positivity associated with 3 different testing approaches: universal testing, HT‐cCMV, and DBS testing. A mixed methods model was created to determine associations between successful HT‐cCMV screening and specific screening protocols. Results Eighty‐two birth hospitals were surveyed from February 2019 to December 2021. Seven thousand six hundred seventy infants underwent universal screening, 9017 infants HT‐cCMV and 535 infants delayed DBS testing. The rates of cCMV positivity were 0.5%, 1.5%, and 7.3%, respectively. The positivity rate for universal CMV screening was less during the COVID‐19 pandemic than that reported prior to the pandemic. There were no statistically significant drops in positivity for any approach during the pandemic. For HT‐cCMV testing, unique order sets and rigorous posttesting protocols were associated with successful screening programs. Conclusion Rates of cCMV positivity differed among the 3 approaches. The rates are comparable to cohort studies reported in the literature. Universal CMV prevalence decreased during the pandemic but not significantly. Institutions with specific order set for CMV testing where the primary care physician orders the test and the nurse facilitates the testing process exhibited higher rates of HT‐cCMV testing.